Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Novel camptothecin derivatives.

Kathleen Legarza1, Li-Xi Yang

  • 1Radiobiology Laboratory, Integrated Radiation Oncology Graduate Medical Education Program, Department of Radiation Oncology, California Pacific Medical Center Research Institute, San Francisco, CA 94118, USA.

In Vivo (Athens, Greece)
|March 31, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Selective Toxicity of a Highly Potent Camptothecin Analogue: A Pilot Study with Glioblastoma Multiforme Cells.

Anticancer research·2016
Same author

A Novel Microtubule-Disrupting Agent Induces Endoplasmic Reticular Stress-Mediated Cell Death in Human Hepatocellular Carcinoma Cells.

PloS one·2015
Same author

Recent developments in radiosensitization.

Anticancer research·2015
Same author

Radiation-associated Cardiac Injury.

Anticancer research·2015
Same author

Cardiotoxicity of molecular-targeted drug therapy.

Anticancer research·2014
Same author

Radioprotectants to reduce the risk of radiation-induced carcinogenesis.

International journal of radiation biology·2013
Same journal

Time-Dependent Inflammatory Cytokine Responses in a Human Fetal Membrane Dual-Compartment Model.

In vivo (Athens, Greece)·2026
Same journal

Impact of COVID-19 Vaccine Type on the Efficacy and Safety of Nivolumab in Patients With Metastatic Non-small-cell Lung Cancer: A Multicenter Study.

In vivo (Athens, Greece)·2026
Same journal

Nutritional Support for Treatment Continuity and Survival in Advanced Gastric Cancer: A Propensity Score-matched Study.

In vivo (Athens, Greece)·2026
Same journal

Efficacy of Switching from Prior Nonsteroidal Anti-inflammatory Drugs to Transdermal Diclofenac in Cancer Pain Management.

In vivo (Athens, Greece)·2026
Same journal

Inhibition of Plasminogen Activator Inhibitor-1 (PAI-1) by Tiplaxtinin Attenuates the Aggressive Phenotype of Vulvar Squamous Cell Carcinoma Cells <i>In Vitro</i>.

In vivo (Athens, Greece)·2026
Same journal

Prognostic Value of Liver Function-based Scores in Hepatocellular Carcinoma Patients Undergoing Liver Transplantation.

In vivo (Athens, Greece)·2026
See all related articles

Researchers are developing novel camptothecin derivatives to improve cancer chemotherapy. These new agents aim to enhance effectiveness while reducing the toxicities associated with the original camptothecin compound.

Area of Science:

  • Oncology
  • Medicinal Chemistry

Background:

  • Camptothecin, discovered in 1958, shows potent anti-cancer activity.
  • High toxicity limited clinical use of the parent compound.
  • Ongoing research focuses on developing safer, more effective analogs.

Purpose of the Study:

  • To review the in vivo and in vitro characteristics of novel camptothecin derivatives.
  • To assess the improved pharmacokinetic and toxicity profiles of these agents.

Main Methods:

  • Review of preclinical data (in vivo and in vitro studies).
  • Analysis of structural modifications to the camptothecin scaffold.
  • Evaluation of efficacy and safety data for derivative compounds.

Main Results:

Related Experiment Videos

  • Novel camptothecin derivatives exhibit promising anti-cancer properties.
  • Modifications have led to improved therapeutic indices compared to the parent compound.
  • Detailed in vivo and in vitro data highlight the potential of these agents.

Conclusions:

  • Camptothecin derivatives represent a significant advancement in cancer chemotherapy.
  • These novel agents offer a potentially improved treatment option for various cancers.
  • Further clinical investigation is warranted for these promising chemotherapeutic agents.